Verastem Oncology

Update in progress

VSTM (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Verastem, Inc. is a development-stage biopharmaceutical company focused on cancer therapies. Its candidates are Avutometinib, an oral dual RAF/MEK inhibitor targeting the RAS/MAPK pathway, and Defactinib, an oral FAK inhibitor for solid tumors. The company runs trials such as RAMP 301, RAMP 201, FRAME, and RAMP 205, and collaborates with Chugai, Pfizer, Amgen, and GenFleet. Based in Needham, MA.

Company score

Sentiment: 0.11; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.28; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive